imt.ie
Cure8 news brief
Why This Matters
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.
Awareness helps patients and clinicians avoid therapies that could worsen the other condition and prompts appropriate screening.
Who Should Pay Attention
Dermatologists, gastroenterologists, adult patients with psoriasis or Crohn’s disease, patients on biologic therapies, and researchers interested in immune pathways linking skin and gut.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
The piece summarizes why psoriasis and Crohn’s disease can co-occur and why the IL-12/23 axis is relevant to both conditions.
It explains that while some biologics targeting IL-23 or the shared p40 subunit have efficacy in both diseases, IL-17 inhibitors work in psoriasis but can worsen or lack efficacy in Crohn’s disease, so they are generally advised against when active IBD is present.
Clinically, the article stresses the need to screen for gastrointestinal symptoms in patients with psoriasis and to document new skin findings in patients with Crohn’s disease.
It also notes that eruptions can be paradoxical during anti-TNF therapy and that dermatology–gastroenterology communication and consideration of product-specific safety information are recommended.
Keep In Mind
The article is a clinical review summarizing existing epidemiological, genetic and immunological evidence and current European/UK guidance. It is not reporting a single new clinical trial result; product-specific safety and SmPC recommendations should be consulted for prescribing decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationimt.ie
AuthorsEditorial Staff
Indexed viaBing News
Source typeWeb article
PublishedSep 4, 2026, 8:05 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Escalating Crohn’s Care: The Case for Dual Therapy
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.